Navigation Links
Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55
Date:10/26/2011

Solution were the result of increased volume.

Gross profit for the nine months ended September 30, 2011 was $1.92 billion and gross margins were 41.7%. For the nine months ended September 30, 2010, gross profit was $1.64 billion and gross margins were 40.8%. Gross profit for the current year-to-date period is impacted by certain purchase accounting related items, of approximately $278.1 million, which consisted primarily of amortization related to purchased intangible assets associated with acquisitions. Excluding such items, gross margins would have been approximately 48%. Prior year gross profit is also impacted by similar purchase accounting related items in the amount of $217.6 million. Excluding such items, gross margins in the prior year would have been approximately 46%. This increase in gross margin is primarily the result of new product launches in North America and favorable pricing on the EpiPen® Auto-Injector.  

Earnings from operations were $758.1 million for the nine months ended September 30, 2011, compared to $627.4 million for the comparable prior year period.  Excluding the impact of purchase accounting related items in both periods, as mentioned above, earnings from operations increased to $1.04 billion in the current nine-month period from $845.0 million in the prior year comparable period, mainly due to an increase in gross profit, as a result of an increase in revenues and gross margin improvement, partially offset by increases in R&D and SG&A expense. Also included in the current nine-month period is $28.5 million of net expense related to the settlement of litigation.  In the comparable prior year period, Mylan recognized net expense from litigation settlements of $14.3 million.  

Interest expense for the nine months ended September 30, 2011, totaled $254.8 million, compared to $240.0 million for comparable prior year period. The increase is primarily due to interest as
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
2. Life Technologies Announces Third Quarter 2011 Results
3. Insmed to Host 2011 Third Quarter Earnings Conference Call
4. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
5. Anthera Announces Third Quarter 2011 Financial Report and Conference Call
6. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
7. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
8. HeartWare Schedules Third Quarter Conference Call and Webcast
9. Dyadic International Announces Date and Time of Third Quarter 2011 Financial Results Release and Conference Call
10. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
11. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... RALEIGH, N.C. , Aug. 20, 2014 /PRNewswire/ ... clinical research services located in Raleigh, ... Bradford Evans as Vice President of ... Administration, Brad will oversee all corporate processes, including ... to joining Clintrax Global, Brad worked as an ...
(Date:8/20/2014)... measuring vibrational motion of a single molecule with a ... a single molecule differs from the behaviour of larger ... the University of California, Irvine, where post-doctoral researcher Eero ... visiting fellow under professor Vartkess A. Apkarian, whose team ... by Professor Eric O. Potma. The results of the ...
(Date:8/20/2014)... -- Decision Resources Group finds that the vascular access device market in ... India and China (BRIC) ... the size of the United States market ... faster growth as a result of strong economic expansion, improving access ... from Decision Resources Group,s coverage of the BRIC vascular access device ...
(Date:8/20/2014)... Not long ago, it was more or ... late in the development cycle – even after the ... suggest that, like many things GxP, expectations for early ... multiple drug sponsors have been required by authorities to ... phase I/II. It’s not only clinical trial material containers ...
Breaking Biology Technology:Clintrax Global, Inc. Announces Addition to Executive Team 2Seeing a molecule breathe 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... N.J., Sept. 12 Schering-Plough,Corporation (NYSE: SGP ) ... aggregate principal amount of 6.00% Senior Notes due 2017 ... due 2037 through,an underwritten registered public offering. The offering ... customary closing conditions. The global coordinator for the ...
... Inc.,(Nasdaq: MEDX ) announced today that it is ... Growth Conference in New York City on Tuesday,September 18, ... be,webcast live and will be available for replay through ... Medarex website via the Internet at, http://www.medarex.com . ...
... SAN DIEGO, Sept. 12 Gen-Probe Incorporated,(Nasdaq: GPRO ... Bank of,America,s 37th Annual Investment Conference in San Francisco ... (5:30 p.m. Eastern Time).,The presentation is scheduled to be ... the investor information section of Gen-Probe,s website,at http://www.gen-probe.com ...
Cached Biology Technology:Schering-Plough Announces Pricing of Senior Notes Offering 2Schering-Plough Announces Pricing of Senior Notes Offering 3Gen-Probe to Webcast Presentation at Bank of America's 37th Annual Investment Conference 2
(Date:8/21/2014)... 18-22, 2014 , WHERE: , San Diego ... CA 92101 , WHAT: , Invited and ... latest research in human genetics. Examples of sessions ... on rare genetic variants in health and disease, ... sun sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) , ...
(Date:8/21/2014)... the journal Carcinogenesis by researchers at the ... protein adenomatous polyposis coli (APC) in suppressing colorectal cancer ... U.S. , Lead author Kristi Neufeld, associate professor in ... Cancer Biology program at the KU Cancer Center, has ... understand the various activities of APC, a protein whose ...
(Date:8/21/2014)... designed by an international standards process, will be available ... an invited review published in the OnlineFirst version of ... the official journal of the American Society for Parenteral ... reduce the occurrence of misconnection that can be harmful ... are used to join medical devices, components, and accessories ...
Breaking Biology News(10 mins):American Society of Human Genetics 2014 Annual Meeting 2Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3New feeding tube connectors will improve patient safety 2
... at Universitat Autnoma de Barcelona (INc-UAB) identified the fundamental ... associated with synaptic activity. The discovery, published in the ... study a new target that could help to understand ... known to cause early cognitive deficit, and the neurodegeneration ...
... NC In a paper published today in the journal ... North Carolina at Chapel Hill demonstrates a simple, cost-effective technique ... the structures, and ultimately the functions, of the RNA molecules ... When cell behavior goes wrong, diseases including cancer and ...
... gene sequencing technology, researchers have demonstrated that the gene ... Leukemia, AML, one of the most common types of ... allows for the rapid and comprehensive detection of gene ... online April 15 in Nature , are a ...
Cached Biology News:Researchers have identified a gene with a key role in neuronal survival 23-D RNA modeling opens scientific doors 2Scientists identify FLT3 gene as a valid therapeutic target in acute myeloid leukemia 2
... U. Desselberger (1995) • This book ... together classical and molecular techniques currently ... infections and analysis of virus-specific antibodies ... are presented covering immunoassays, blotting and ...
...
... Kits provide rapid and efficient removal of ... and salts from PCR products (Figure 1). ... two Binding Buffer options for fragments >100 ... performed in either single column or 96-well ...
... Blunt TOPO PCR Cloning Kit offers ... high-efficiency (>=95%) cloning of blunt-end PCR ... The kit includes the linearized and ... 5-minute bench-top ligations without ligase (1). ...
Biology Products: